INDIVIOR PHARMACEUTICALS INC (INDV) Stock Fundamental Analysis

NASDAQ:INDV • US45579U1097

32.72 USD
-0.99 (-2.94%)
At close: Feb 27, 2026
32.72 USD
0 (0%)
After Hours: 2/27/2026, 8:11:13 PM
Fundamental Rating

5

Overall INDV gets a fundamental rating of 5 out of 10. We evaluated INDV against 193 industry peers in the Pharmaceuticals industry. While INDV has a great profitability rating, there are some minor concerns on its financial health. INDV has a bad growth rate and is valued cheaply.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • INDV had positive earnings in the past year.
  • INDV had a positive operating cash flow in the past year.
  • In multiple years INDV reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: INDV reported negative operating cash flow in multiple years.
INDV Yearly Net Income VS EBIT VS OCF VS FCFINDV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

  • The Return On Assets of INDV (8.62%) is better than 89.64% of its industry peers.
  • INDV's Return On Invested Capital of 50.62% is amongst the best of the industry. INDV outperforms 100.00% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for INDV is significantly above the industry average of 12.93%.
  • The 3 year average ROIC (43.06%) for INDV is below the current ROIC(50.62%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 8.62%
ROE N/A
ROIC 50.62%
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
INDV Yearly ROA, ROE, ROICINDV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300 400

1.3 Margins

  • With an excellent Profit Margin value of 10.34%, INDV belongs to the best of the industry, outperforming 84.46% of the companies in the same industry.
  • INDV's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 24.49%, INDV belongs to the top of the industry, outperforming 92.23% of the companies in the same industry.
  • In the last couple of years the Operating Margin of INDV has remained more or less at the same level.
  • INDV has a Gross Margin of 85.51%. This is amongst the best in the industry. INDV outperforms 89.12% of its industry peers.
  • INDV's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 24.49%
PM (TTM) 10.34%
GM 85.51%
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
INDV Yearly Profit, Operating, Gross MarginsINDV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

4

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), INDV is creating value.
  • There is no outstanding debt for INDV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INDV Yearly Shares OutstandingINDV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
INDV Yearly Total Debt VS Total AssetsINDV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • INDV has an Altman-Z score of 2.64. This is not the best score and indicates that INDV is in the grey zone with still only limited risk for bankruptcy at the moment.
  • INDV has a Altman-Z score of 2.64. This is in the better half of the industry: INDV outperforms 68.39% of its industry peers.
  • INDV has a debt to FCF ratio of 2.68. This is a good value and a sign of high solvency as INDV would need 2.68 years to pay back of all of its debts.
  • INDV has a better Debt to FCF ratio (2.68) than 93.26% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.68
Altman-Z 2.64
ROIC/WACC5.38
WACC9.41%
INDV Yearly LT Debt VS Equity VS FCFINDV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • INDV has a Current Ratio of 0.96. This is a bad value and indicates that INDV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • INDV has a worse Current ratio (0.96) than 84.97% of its industry peers.
  • INDV has a Quick Ratio of 0.96. This is a bad value and indicates that INDV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.79, INDV is not doing good in the industry: 80.83% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.79
INDV Yearly Current Assets VS Current LiabilitesINDV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2

3. Growth

3.1 Past

  • INDV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 459.09%, which is quite impressive.
EPS 1Y (TTM)459.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%156.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.13%

3.2 Future

  • Based on estimates for the next years, INDV will show a decrease in Earnings Per Share. The EPS will decrease by -3.07% on average per year.
  • INDV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.79% yearly.
EPS Next Y22.44%
EPS Next 2Y15.88%
EPS Next 3Y-10.86%
EPS Next 5Y-3.07%
Revenue Next Year-3.87%
Revenue Next 2Y0.57%
Revenue Next 3Y-0.58%
Revenue Next 5Y0.79%

3.3 Evolution

INDV Yearly Revenue VS EstimatesINDV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
INDV Yearly EPS VS EstimatesINDV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 1 2 3

8

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 13.30, which indicates a correct valuation of INDV.
  • 88.60% of the companies in the same industry are more expensive than INDV, based on the Price/Earnings ratio.
  • INDV is valuated cheaply when we compare the Price/Earnings ratio to 27.07, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 10.86, the valuation of INDV can be described as reasonable.
  • Based on the Price/Forward Earnings ratio, INDV is valued cheaper than 87.56% of the companies in the same industry.
  • INDV's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.05.
Industry RankSector Rank
PE 13.3
Fwd PE 10.86
INDV Price Earnings VS Forward Price EarningsINDV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 84.46% of the companies in the same industry are more expensive than INDV, based on the Enterprise Value to EBITDA ratio.
  • 81.35% of the companies in the same industry are more expensive than INDV, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 34.04
EV/EBITDA 12.58
INDV Per share dataINDV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • INDV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of INDV may justify a higher PE ratio.
  • A cheap valuation may be justified as INDV's earnings are expected to decrease with -10.86% in the coming years.
PEG (NY)0.59
PEG (5Y)N/A
EPS Next 2Y15.88%
EPS Next 3Y-10.86%

0

5. Dividend

5.1 Amount

  • INDV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

INDIVIOR PHARMACEUTICALS INC

NASDAQ:INDV (2/27/2026, 8:11:13 PM)

After market: 32.72 0 (0%)

32.72

-0.99 (-2.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)04-22
Inst Owners92.33%
Inst Owner Change-70.46%
Ins Owners3.78%
Ins Owner Change31.01%
Market Cap4.09B
Revenue(TTM)N/A
Net Income(TTM)122.00M
Analysts84.62
Price Target46.48 (42.05%)
Short Float %10.17%
Short Ratio5.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)81.89%
Min EPS beat(2)71.47%
Max EPS beat(2)92.31%
EPS beat(4)4
Avg EPS beat(4)70.49%
Min EPS beat(4)45.92%
Max EPS beat(4)92.31%
EPS beat(8)6
Avg EPS beat(8)12.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.31%
Min Revenue beat(2)17.53%
Max Revenue beat(2)21.1%
Revenue beat(4)4
Avg Revenue beat(4)14.97%
Min Revenue beat(4)8.6%
Max Revenue beat(4)21.1%
Revenue beat(8)5
Avg Revenue beat(8)7.48%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.33%
PT rev (3m)24.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.31%
EPS NY rev (1m)0%
EPS NY rev (3m)79.73%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.81%
Valuation
Industry RankSector Rank
PE 13.3
Fwd PE 10.86
P/S 3.46
P/FCF 34.04
P/OCF 22.69
P/B N/A
P/tB N/A
EV/EBITDA 12.58
EPS(TTM)2.46
EY7.52%
EPS(NY)3.01
Fwd EY9.21%
FCF(TTM)0.96
FCFY2.94%
OCF(TTM)1.44
OCFY4.41%
SpS9.45
BVpS-1.66
TBVpS-1.67
PEG (NY)0.59
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 8.62%
ROE N/A
ROCE 64.08%
ROIC 50.62%
ROICexc 3805.17%
ROICexgc 5707.75%
OM 24.49%
PM (TTM) 10.34%
GM 85.51%
FCFM 10.17%
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)54.5%
ROCE(5y)38.6%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
F-Score8
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.68
Debt/EBITDA 0.97
Cap/Depr 230.77%
Cap/Sales 5.08%
Interest Coverage 250
Cash Conversion 57.14%
Profit Quality 98.36%
Current Ratio 0.96
Quick Ratio 0.79
Altman-Z 2.64
F-Score8
WACC9.41%
ROIC/WACC5.38
Cap/Depr(3y)163.83%
Cap/Depr(5y)132.28%
Cap/Sales(3y)2.67%
Cap/Sales(5y)2.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)459.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%156.25%
EPS Next Y22.44%
EPS Next 2Y15.88%
EPS Next 3Y-10.86%
EPS Next 5Y-3.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.13%
Revenue Next Year-3.87%
Revenue Next 2Y0.57%
Revenue Next 3Y-0.58%
Revenue Next 5Y0.79%
EBIT growth 1Y8.24%
EBIT growth 3Y11.69%
EBIT growth 5Y7.28%
EBIT Next Year1050.98%
EBIT Next 3Y148.27%
EBIT Next 5Y64.69%
FCF growth 1Y236.36%
FCF growth 3Y-74.97%
FCF growth 5Y-48.94%
OCF growth 1Y446.15%
OCF growth 3Y-53.28%
OCF growth 5Y-24.93%

INDIVIOR PHARMACEUTICALS INC / INDV FAQ

What is the fundamental rating for INDV stock?

ChartMill assigns a fundamental rating of 5 / 10 to INDV.


What is the valuation status of INDIVIOR PHARMACEUTICALS INC (INDV) stock?

ChartMill assigns a valuation rating of 8 / 10 to INDIVIOR PHARMACEUTICALS INC (INDV). This can be considered as Undervalued.


What is the profitability of INDV stock?

INDIVIOR PHARMACEUTICALS INC (INDV) has a profitability rating of 7 / 10.


How financially healthy is INDIVIOR PHARMACEUTICALS INC?

The financial health rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 4 / 10.


Is the dividend of INDIVIOR PHARMACEUTICALS INC sustainable?

The dividend rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 0 / 10 and the dividend payout ratio is 0%.